Created at	Source	Raw Value	Validated value
March 23, 2024, midnight	usa	Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose;Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First Dose;Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After Second Dose;Parts A and B: Number of Participants With Medically Attended AEs (MAAEs) and AEs Leading to Discontinuation;Parts A and B: Number of Participants With Serious AEs (SAEs)	Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose;Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First Dose;Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After Second Dose;Parts A and B: Number of Participants With Medically Attended AEs (MAAEs) and AEs Leading to Discontinuation;Parts A and B: Number of Participants With Serious AEs (SAEs)
Feb. 18, 2021, 12:31 a.m.	usa	Efficacy: Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of mRNA-1273;Safety: Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal;Safety: Number of Participants with Serious AEs (SAEs);Safety: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Safety: Number of Participants with Unsolicited AEs	Efficacy: Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of mRNA-1273;Safety: Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal;Safety: Number of Participants with Serious AEs (SAEs);Safety: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Safety: Number of Participants with Unsolicited AEs
Oct. 26, 2020, 11:31 p.m.	usa	Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of mRNA-1273;Number of Participants with Unsolicited AEs;Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal	Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of mRNA-1273;Number of Participants with Unsolicited AEs;Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal